A5052379271- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Advanced Breast Cancer Therapies
- Lung Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Occupational and environmental lung diseases
- HER2/EGFR in Cancer Research
- Global Cancer Incidence and Screening
- Health Systems, Economic Evaluations, Quality of Life
- Palliative Care and End-of-Life Issues
- Pleural and Pulmonary Diseases
- Medical Imaging and Pathology Studies
- Cancer Treatment and Pharmacology
- Cancer survivorship and care
- Pancreatic and Hepatic Oncology Research
- Head and Neck Cancer Studies
- Multiple and Secondary Primary Cancers
- Advances in Oncology and Radiotherapy
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lymphoma Diagnosis and Treatment
Ottawa Hospital
2016-2025
University of Ottawa
2016-2025
Ottawa Hospital Research Institute
2015-2024
University of Toronto
2007-2024
Princess Margaret Cancer Centre
2007-2024
Centre Hospitalier de l’Université de Montréal
2024
Wilfrid Laurier University
2023
Ottawa University
2017-2023
First Hospital of China Medical University
2019
Ottawa Regional Cancer Foundation
2019
Abstract Purpose: Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall (OS) benefit in the phase III MONALEESA-7 trial of pre-/perimenopausal patients with hormone receptor (HR)-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC). The median OS was not reached ribociclib arm protocol-specified final analysis; we hence performed an exploratory additional outcomes analysis extended follow-up (median, 53.5 months)....
Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to immunotherapy. BR.36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of molecular response-adaptive immuno-chemotherapy for patients with lung cancer. In the first two independent stages, 50 advanced non-small cell cancer received pembrolizumab as standard care. The objectives stage 1 were ascertain ctDNA response and determine optimal timing concordance radiologic Response Evaluation Criteria...
Abstract For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy anti-PD-(L)1 checkpoint inhibitors, alone or platinum-doublet therapy. However, not all derive durable benefit and resistance to immune blockade common. Understanding mechanisms of resistance—which can include defects in DNA damage response repair pathways, alterations functional mutations STK11 /LKB1, antigen-presentation...
Purpose National Cancer Institute of Canada Clinical Trials Group Study BR.21 established erlotinib as a standard care in patients with non–small-cell lung cancer (NSCLC) after failure first- or second-line chemotherapy. The current study analyzes the influence age on outcomes BR.21. Patients and Methods was double-blind phase III trial that randomly assigned 731 to 150 mg daily placebo. End points included progression-free survival overall (OS), response, quality life (QOL), drug exposure,...
In malignant mesothelioma (MM), radiologic assessment of disease status is difficult. Both soluble mesothelin-related peptide (SMRP) and osteopontin (OP) have utility in distinguishing MM from benign pleural disease. We evaluated whether SMRP OP also correlated with the course MM.Serial plasma samples patients were prospectively collected, levels measured. Radiologic tests across time periods showing progression, stability, or shrinkage compared corresponding changes SMRP/OP levels.From 41...
Bone metastases (BM) are common in NSCLC patients. Despite some potential positive effects of bone-targeted therapies, their use is infrequent, which may relate to the overall poor prognosis advanced lung cancer. We reviewed literature evaluate incidence, consequences and bone-targeting agents cancer patients with BM both trial non-trial clinical setting.Published prospective retrospective papers investigating BM, settings, were identified discussed this review.BM often present...
Determine the efficacy and safety of first-line ribociclib plus letrozole in elderly patients with HR+, HER2− advanced breast cancer. 668 postmenopausal women cancer no prior systemic therapy for disease were enrolled Phase III MONALEESA-2 trial (NCT01958021); 295 aged ≥ 65 years. Patients randomized to (600 mg/day; 3-weeks-on/1-week-off) (2.5 mg/day) or placebo until progression, unacceptable toxicity, death, treatment discontinuation. The primary endpoint was PFS, which evaluated (≥ years)...
Liquid biopsy (LB) can detect actionable genomic alterations in plasma circulating tumor DNA beyond tissue testing (TT) alone advanced non-small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of adding LB to TT Canadian healthcare system.
IntroductionIn the phase II ATLANTIC study, durvalumab provided durable responses with acceptable tolerability in heavily pretreated patients advanced NSCLC, across three independent patient cohorts defined by EGFR/ALK status and tumour PD-L1 expression. Preliminary overall survival (OS) data were encouraging. We now report final OS updated safety data.MethodsPatients NSCLC disease progression following ≥2 previous systemic regimens received 10 mg/kg every 2 weeks. The primary endpoint was...
Background: The Ottawa Hospital (TOH) defined delay to timely lung cancer care as a system design problem. Recognizing the patient need for an integrated journey and dynamic alignment of providers, TOH used learning health (LHS) vision redesign regional diagnostic processes. A LHS is driven by feedback utilizing operational clinical information drive optimization innovation. An essential component collaborative platform that provides connectivity across silos, organizations, professions....